{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:49:04Z","timestamp":1785908944738,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102625","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:05:28Z","timestamp":1783955128000},"page":"102625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"prefix":"10.1016","volume":"24","author":[{"given":"Ahmad","family":"Basharat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shaheer","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Raffey","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waqas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juskaran","family":"Chadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moazzam","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clgc.2026.102625_bib0001","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.clgc.2026.102625_bib0002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102625_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2026.102625_bib0004","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9747","key":"10.1016\/j.clgc.2026.102625_bib0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer (TROPIC): a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102625_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102625_bib0007","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102625_bib0008","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102625_bib0009","article-title":"Activity of platinum-based chemotherapy in advanced prostate cancer: a systematic review and meta-analysis","volume":"3","author":"Schmid","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.clgc.2026.102625_bib0010","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clgc.2026.102625_bib0011","article-title":"Effectiveness of platinum-based chemotherapy in metastatic prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Leal","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"31","key":"10.1016\/j.clgc.2026.102625_bib0012","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102625_bib0013","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102625_bib0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.clgc.2026.102625_bib0015","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m\u00b2) and the currently approved dose (25 mg\/m\u00b2) in post-docetaxel patients with metastatic castration-resistant prostate cancer (PROSELICA)","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.clgc.2026.102625_bib0016","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer (FIRSTANA): a randomised phase III trial","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102625_bib0017","first-page":"293","article-title":"Observational study of cabazitaxel in metastatic castration-resistant prostate cancer: CAPRISTANA","volume":"123","author":"Carles","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2026.102625_bib0018","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","article-title":"Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer","volume":"124","author":"Lozano","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2026.102625_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102625_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102625_bib0021","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2026.102625_bib0022","unstructured":"ClinicalTrials.gov. Cabazitaxel with or without carboplatin in aggressive variant prostate cancer. Identifier: NCT06470243. Available from: https:\/\/clinicaltrials.gov. Accessed: March 29, 2026"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:21:02Z","timestamp":1785907262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326001254"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102625","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102625"}}